Clinical Pathology Interpretation in Dogs And Nonhuman Primates in Preclinical Studies

Dogs and nonhuman primates (NHPs), particularly Beagle dogs and cynomolgus or rhesus macaques, are essential large animal models in preclinical drug development. Their physiological similarities to humans provide translational value for safety, pharmacology, and biomarker evaluation.

Unlike rodents, large animals accommodate repeated blood sampling and larger sample volumes, enabling concurrent pharmacokinetic (PK), toxicokinetic (TK), and clinical pathology assessments. However, interpreting clinical pathology data in these species is confounded by biological variability, study design, animal origin, and experimental procedures. Distinguishing true test article-related toxicity from physiological drift or procedural artifacts requires a comprehensive understanding of these variables.

In large animal studies, cohort sizes are inherently limited due to ethical and practical constraints. Consequently, pre-dose baseline data are critical. Conducting multiple pre-dose evaluations allows investigators to:

• Establish each animal as its own longitudinal control.
• Quantify individual biological variability.
• Identify and exclude outliers or unhealthy animals prior to randomization.
• Differentiate handling-induced stress responses from baseline physiology.

Individual variation is particularly pronounced in NHPs compared to purpose-bred rodents or dogs. Baseline anomalies often include fluctuant erythrocyte parameters, sporadic elevations in hepatic enzymes, or atypical protein profiles. If these baseline variations overlap with the anticipated pharmacological target or toxicological profile of the test article, pre-dose screening serves as the primary mechanism to prevent false-positive interpretations.

Frequent phlebotomy for pharmacokinetic profiling can induce iatrogenic hematological shifts. High-frequency or high-volume blood collection frequently causes declines in:

• Red blood cell (RBC) count
• Hemoglobin (Hgb) concentration
• Hematocrit (Hct)
• Total protein and albumin (due to hemodilution)

If bone marrow function remains intact, these microcytic or normocytic changes are typically accompanied by a compensatory reticulocytosis. Therefore, mild declines in erythron parameters must be cross-referenced with total blood volumes drawn throughout the study.

NHP protocols routinely require anesthesia for restraint, imaging, or invasive sampling. The choice and duration of anesthesia directly impact clinical pathology readouts. Anesthetized animals frequently exhibit altered leukocyte distributions and shifted electrolyte profiles compared to conscious, manually restrained cohorts. Furthermore, recumbency and intramuscular anesthetic injections can cause subclinical muscle trauma, leading to marked spikes in creatine kinase (CK). Consistent sampling techniques and standardized anesthetic protocols are mandatory across all study phases.

Additional study design variables requiring strict control include:

• Animal age and developmental stage
• Fasting duration and timing relative to collection
• Order of sampling within a cohort
• Route and rate of administration
• Compounding experimental procedures (e.g., surgical dosing, continuous infusions)

Dogs and NHPs possess longer erythrocyte lifespans than rodents, altering the kinetics of anemia development and marrow recovery. Following acute blood loss, large animals demonstrate a lower baseline reticulocyte percentage and a more gradual regenerative response.

In macaques, baseline erythrocyte characteristics (such as mean corpuscular volume) correlate with geographic origin (e.g., Chinese vs. Cambodian vs. Mauritian cynomolgus monkeys). Utilizing animals from a single geographic source minimizes baseline noise. Additionally, subclinical background pathogens (such as hemoparasites or latent viral infections) can suppress erythropoiesis and must be screened out during quarantine.

Leukocyte profiles are highly species-specific. Dogs are neutrophil-dominant, whereas healthy NHPs exhibit a more balanced or lymphocyte-dominant distribution. These baseline differences dictate distinct manifestation patterns during systemic inflammation.

Furthermore, physical restraint, novel environments, or fear triggers rapid catecholamine and glucocorticoid release. This stress response induces marginal pool mobilization, presenting as transient neutrophilia and lymphopenia. Because NHPs are highly sensitive to handling stress, isolated shifts in white blood cell counts-absent correlative clinical signs or histopathological evidence of tissue inflammation-should be interpreted with caution.

Coagulation kinetics vary by species. Baseline prothrombin time (PT) is inherently shorter in dogs than in humans, and idiosyncratic factor deficiencies can cause isolated, non-drug-related PT prolongation in individual dogs. In NHP studies, activated partial thromboplastin time (APTT) assays are highly sensitive to reagent batch variability and sample handling (e.g., partial clotting during collection). When the coagulation cascade is a known target of the test article, tight baseline matching and uniform reagent lots are imperative.

Alanine aminotransferase (ALT) is a standard biomarker for hepatocellular leakage. In young, purpose-bred Beagle dogs, baseline ALT ranges are narrow, allowing for the detection of subtle, treatment-induced hepatic changes. Conversely, older dogs and NHPs display wider physiological variation.

Macaques frequently exhibit transient, self-limiting ALT spikes due to background hepatic changes or subclinical viral flares. Consequently, single-point elevations in liver enzymes require corroboration via concurrent biomarkers (e.g., aspartate aminotransferase, total bile acids), functional assays, and histopathological evaluation.

Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) serve as indicators of hepatobiliary or cholestatic disease. While ALP is highly sensitive to cholestasis in dogs, it is less specific in NHPs due to significant bone and intestinal isoenzyme contributions, particularly in juvenile, growing animals. GGT is often a more reliable biliary marker in NHP models.

Blood urea nitrogen (BUN) and serum creatinine remain the standard indicators of glomerular filtration, despite their insensitivity to early-stage renal impairment. Dogs maintain relatively narrow physiological ranges for these analytes, simplifying the identification of mild renal changes. In contrast, NHPs present a broad baseline range, making subtle shifts harder to characterize.

Because BUN is influenced by protein catabolism, dietary intake, and hydration state, it must be interpreted alongside creatinine. Urinalysis provides essential context, but sample collection in large animals-often involving overnight pan collection-introduces risks of evaporation, fecal contamination, or cellular degradation. When nephrotoxicity is a primary concern, timed, ultrasound-guided cystoscopy or specialized metabolic caging is recommended.

Creatine kinase (CK) elevations are common in NHP studies. They are frequently driven by physical capture, restraint, intramuscular injections, or prolonged recumbency under anesthesia rather than systemic test article toxicity. To prevent misinterpretation, isolated CK spikes should be evaluated against:

• Chronological proximity to stressful events or injections
• Clear dose-dependency across treatment groups
• Co-activation of more specific tissue markers
• Concurrent changes in aspartate aminotransferase (AST) and lactate dehydrogenase (LDH)

For cardiotoxicity assessments, cardiac troponins (I or T) should be utilized, as they offer superior cardiospecificity over traditional enzymatic markers in both dogs and NHPs.

Glucose and lipid metabolism in NHPs are highly sensitive to environmental stressors and dietary shifts. Handling-induced epinephrine release routinely triggers rapid glycogenolysis, resulting in transient hyperglycemia. Feeding schedules also cause pronounced fluctuations in serum triglycerides and cholesterol.

NHPs also exhibit higher and more variable baseline serum protein concentrations than rodents. Shifts in albumin and globulin fractions frequently reflect non-specific acute-phase inflammatory responses to procedures, subclinical infections, or altered nutritional states, rather than direct target-organ toxicity.

Serum electrolyte concentrations, particularly sodium, potassium, and chloride, are subject to rapid shifts in NHPs due to hydration status, acid-base imbalances from anesthesia-induced respiratory depression, or sample hemolysis.

Total calcium concentrations are directly bound to serum albumin. Consequently, alterations in total calcium must be mathematically or physiologically corrected for albumin levels; changes in total calcium do not necessarily indicate a biologically relevant shift in the functional, ionized calcium fraction.

Interpreting clinical pathology data in dogs and nonhuman primates extends beyond standard statistical comparisons between vehicle and treatment groups. Biological variability, baseline drifting, phlebotomy artifacts, anesthesia, and handling stress frequently introduce confounding data.

Accurate safety assessment relies on the holistic integration of clinical pathology parameters with study design parameters, real-time clinical observations, pharmacokinetic exposure data, and definitive histopathological outcomes. A rigorous, species-specific approach to these datasets is essential for translating preclinical findings into accurate human risk assessments.

Contact Prisys Biotech

Hall, R. L., & Everds, N. E. (2003). Factors affecting the interpretation of canine and nonhuman primate clinical pathology. Toxicologic pathology, 31(1_suppl), 6-10.  DOI: 10.1080/01926230390174878